W., Firman S.
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Brolucizumab for Wet Aged-Related Macular Degeneration Patients : too Good to be True: Oral Presentation - Observational Study - Resident Purbonegoro, Tania; Prayogo, M. Eko; Agni, A. Nurini; W., Tri Wahyu; Supanji; W., Firman S.; Sasongko, M.B
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/jtysr533

Abstract

Introduction & ObjectivesBrolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF). It showed superioranatomic outcomes and noninferiority best corrected visual acuity (BCVA) results for Wet Aged-Related Macular Degeneration (Wet-AMD) compared to other anti-VEGF. In Yogyakarta, it's beenonly used in a few patients and we want to report the effectiveness and safety of brolucizumab inWetAMD MethodsIn this retrospective study, all wetAMD patients who underwent Brolucizuab intravitreal injectionsbetween December 2021 and January 2023 at Dr YAP Eye Hospital were studied. Patient’sdemographic data, before and after intravitreal brolucizumab injections (central macular thickness,intraocular pressure, and BCVA) were assessed. ResultsThis study included 6 eyes of 6 patients (3 women) with a mean age of 69.5 years old. The meanfollow-up period was 27 ± 10.1 weeks after the first injection of brolucizumab. Three patients werenaïve wetAMD patients, three anti-VEGF experienced wetAMD patients. The mean BCVA at baseline(before brolucizumab injection) was 0.12 decimal (6/48) and 0.29 decimal (6/20) at the last followup.Five out of six patients' visual acuity were improved. In four out of six patient central macularthickness were reduced (mean difference 29,2 um). None of the patient's intraocular pressureincreased over 21 mmHg. None of the patients reported any signs of inflammation, vasculitis, ocularor systemic adverse effects. ConclusionThis limited data demonstrated that brolucizumab was relatively safe and effective in stabilizingBCVA for both WetAMD patients who had previous treatment with other anti-VEGF agents andnaive. Larger sample sizes studies & future multicenter collaborative are warranted
Sutureless Scleral Fixation of Intraocular Lens in Aphakia: Characteristics and Visual Outcomes: Oral Presentation - Observational Study - Resident Rahma, Fatkhati Saida; W., Firman S.; A, Angela Nurini; W, Tri Wahyu; Supanji; Sasongko, M. Bayu
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/gqh2r204

Abstract

Introduction & ObjectivesSutureless scleral fixation (SSF) surgery is one of the secondary intraocular lens (IOL) implantationprocedures for aphakic patients with absent or deficient capsular bag support that is beingincreasingly performed these days. This study aimed to describe the characteristics, indications for,and visual outcomes of patients who had undergone sutureless scleral fixation of intraocular lensesat Sardjito Hospital. MethodsA retrospective cross-sectional study of 43 eyes that SSF intraocular lens at Sardjito Hospital,Yogyakarta. The data were collected from electronic medical records of patients from October 2020to December 2022. The data were analyzed descriptively by presenting numbers and percentages forcategorical variables and mean ± standard deviation (SD) for numerical variables. Outcomesincluded pre- and postoperative uncorrected visual acuity (UCVA). ResultsThere were 43 eyes obtained from 40 patients who underwent SSF intraocular lens in this study,consisting of 35 males (79.55%) and 9 females (20.45%). The mean age of the subjects was 50.04 ±19.2 years. Lens subluxation was the most common indication for surgery (32.5%), followed bydropped nucleus (20.45%), intraocular lens luxation (18.18%), lens luxation (15.91%), intraocularlens decentration (9.09%), and endophthalmitis (4.55%). Before surgery, most of the patients hadvisual acuity of less than 3/60 (81.4%) and after surgery, 32.56% had ?6/18, 34.88% had <6/18-6/60,and 18.60% had <6/60-3/60. ConclusionMales predominantly underwent SSF intraocular lens surgery at Sardjito Hospital. Lens subluxationwas the most common indication for the surgery. There was an improvement in visual outcome.